Literature DB >> 2433225

Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.

H Makino, T Saijo, Y Ashida, H Kuriki, Y Maki.   

Abstract

Amlexanox markedly inhibits histamine release from rat mast cells. To clarify the mechanism of this inhibition, we investigated the effect of amlexanox on cAMP content, which, when increased, inhibits histamine release in rat peritoneal mast cells. At concentrations of 10(-8)-10(-6)M, amlexanox or isoproterenol increased the cAMP content of mast cells over that of control cells about 2-fold. When the mast cells were incubated with 10(-8), 10(-7) and 10(-6) M of amlexanox combined with 10(-7) M isoproterenol, the cAMP contents were synergistically increased 15-, 60- and 88-fold, respectively. 3-Isobutyl-1-methylxanthine (IBMX) at 10(-6)-10(-4) M increased the cAMP content 1.7-3.8-fold, and a combination of 10(-4) M IBMX and 10(-7) M isoproterenol synergistically increased the cAMP content 41-fold. A combination of amlexanox and IBMX synergistically increased the cAMP content 19-fold. The increase in cAMP content, when amlexanox and isoproterenol were combined, was transient; it peaked at 0.5 min after the drugs were administered, then decreased to 20-30% of the peak value about 2 min later. Pretreatment of mast cells with amlexanox reduced the effect of the combination of amlexanox and isoproterenol, indicating tachyphylaxis; pretreatment with IBMX had no such effect. The cAMP content of macrophages was also increased by amlexanox, but when combined with isoproterenol or PGE2, the effect was additive. Amlexanox inhibited cAMP phosphodiesterase in rat mast cells; its IC50 value was 1.4 X 10(-5) M, and its inhibitory activity was half that of IBMX.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433225     DOI: 10.1159/000234292

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  22 in total

1.  Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells.

Authors:  M Takei; K Endo; K Takahashi
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  Inhibition of mast cell-dependent anaphylaxis by sodium salicylate.

Authors:  H M Kim; H Y Shin; Y K Choo; J K Park
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes.

Authors:  Xinmin Gan; Michael W Wilson; Tyler S Beyett; Bo Wen; Duxin Sun; Scott D Larsen; John J G Tesmer; Alan R Saltiel; Hollis D Showalter
Journal:  J Labelled Comp Radiopharm       Date:  2019-04-03       Impact factor: 1.921

4.  Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.

Authors:  Elif A Oral; Shannon M Reilly; Andrew V Gomez; Rasimcan Meral; Laura Butz; Nevin Ajluni; Thomas L Chenevert; Evgenia Korytnaya; Adam H Neidert; Rita Hench; Diana Rus; Jeffrey F Horowitz; BreAnne Poirier; Peng Zhao; Kim Lehmann; Mohit Jain; Ruth Yu; Christopher Liddle; Maryam Ahmadian; Michael Downes; Ronald M Evans; Alan R Saltiel
Journal:  Cell Metab       Date:  2017-07-05       Impact factor: 27.287

5.  Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action.

Authors:  H Makino; T Saijo; Y Maki
Journal:  Agents Actions       Date:  1989-11

Review 6.  Therapeutics based on stop codon readthrough.

Authors:  Kim M Keeling; Xiaojiao Xue; Gwen Gunn; David M Bedwell
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-18       Impact factor: 8.929

7.  Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition.

Authors:  Tyler S Beyett; Xinmin Gan; Shannon M Reilly; Louise Chang; Andrew V Gomez; Alan R Saltiel; Hollis D Showalter; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2018-08-06       Impact factor: 4.436

Review 8.  Targeting adipose tissue in the treatment of obesity-associated diabetes.

Authors:  Christine M Kusminski; Perry E Bickel; Philipp E Scherer
Journal:  Nat Rev Drug Discov       Date:  2016-06-03       Impact factor: 84.694

9.  FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.

Authors:  Shannon M Reilly; Mohammad Abu-Odeh; Magdalene Ameka; Julia H DeLuca; Meghan C Naber; Benyamin Dadpey; Nima Ebadat; Andrew V Gomez; Xiaoling Peng; BreAnne Poirier; Elyse Walk; Matthew J Potthoff; Alan R Saltiel
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 10.  Therapeutic promise of engineered nonsense suppressor tRNAs.

Authors:  Joseph J Porter; Christina S Heil; John D Lueck
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-02-10       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.